This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Boehringer’s provisional injunction against Zentiva rejected by UPC

( May 8, 2025, 13:52 GMT | Official Statement) -- MLex Summary: The Court of First Instance of the Unified Patent Court in Lisbon has rejected a provisional injunction requested by Boehringer Ingelheim International against Zentiva Portugal. The case concerned EP 1,830,843, which protects nintedanib — a lung-disease drug — against imminent patent-infringement risks. Boehringer had claimed that Zentiva intended to launch infringing generic drugs, but the court found insufficient evidence of imminent infringement. Consequently, the provisional injunction was rejected and Boehringer was ordered to pay interim costs.The order is attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections